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Abstract
Transient myeloproliferative disorder (TMD) is a leukemia type that occurs typically in newborns.
In Down syndrome, TMD is referred to as transient abnormal myelopoiesis (TAM).32 Recently,
transientness has also been reported in acute myeloid leukemia patients with germline trisomy
21mosaicism, and even in cases with somatic trisomy 21, with or withoutGATA1mutations. TMD
cases without trisomy 21 are rare, and recurrent genetic aberrations that aid in clinical decision-
making are scarcely described. We describe here a TMD patient without trisomy 21 or GATA1
mutation in whom single-nucleotide polymorphism analysis of leukemic blasts revealed a novel
combined submicroscopic deletion (5q31.1–5q31.3 and 8q23.2q24).
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1 INTRODUCTION
Transient myeloid leukemia occurs typically in newborns with
Down syndrome (DS) and is classified by the WHO as transient
abnormal myelopoiesis (TAM).28,32 Clinical characteristics of TAM
vary from asymptomatic presentation to serious conditions with
hepatosplenomegaly, breathing problems and hemorrhage, based
on megakaryocytic hyperproliferation, leukocytosis, anemia and
thrombocytopenia.1,20,28,31,34 Germline trisomy 21 and prenatal
acquired somatic GATA1mutations are considered to be pathognomic
for TAM.1–3,29,31 More recently, transient leukemia has also been
reported in patients with germline trisomy 21 mosaicism and even
with somatic trisomy 21, with or withoutGATA1mutations.2,3
Non-DS transient myeloid leukemia without germline or somatic
trisomy 21 is very rare, and these cases are challenging with
Abbreviations: AMKL, acutemegakaryoblastic leukemia; AML, acutemyeloid leukemia; BM,
bonemarrow; CN-LOH, copy-neutral loss-of-heterozygosity; CN-loss, copy number loss; DS,
Down syndrome; FISH, fluorescence in situ hybridization; JMML, juvenile myelomonocytic
leukemia; PB, peripheral blood; PCR, polymerase chain reaction; SNP, single-nucleotide
polymorphism; TAM, transient abnormal myelopoiesis; TMD, transient myeloproliferative
disorder;WBC, white blood cells.
regard to clinical decision-making, as the alternative to a watch-and-
wait strategy is highly intensive treatment. TMD has mainly been
described in hyperproliferative germline RAS-mutated transient juve-
nile myelomonocytic leukemia (JMML) or oligoclonal monoblastic
TMD cases with germline THPO gene mutations.4,20 In addition, tran-
sient myelomonocytic leukemia harboring t(8;16) has been reported.5
In transient non-DS acute myeloid leukemia (AML) M7 cases without
any trisomy 21, only trisomy 12 and subclonal deletions of chromo-
some 7, 8 and 13 have been reported. We describe here a non-DS
TMDpatientwithout (subclonal) trisomy21 inwhomsingle-nucleotide
polymorphism (SNP) analysis of leukemic blasts revealed a novel
submicroscopic genetic aberration.
2 CASE REPORT
Wescreened the patient (35,5/7weeks gestation) at the age of 12days
with myeloid blasts in peripheral blood (PB) (Fig. 1), without pheno-
typical DS suspicion, hepatosplenomegaly, or other clinical leukemia
signs. Mild dysmorphic signs included straight eyebrows, merging into
the lateral hairlines, a long philtrum and thin upper vermillion of the
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F IGURE 1 Peripheral blood cell counts over time (days) in TMD
patient described in the report. This indicates BM analysis. Platelets
rise while myeloblasts and leukocytes (absolute numbers) are return-
ing to normal values over time. At birth: maximum hemoglobin
22.7 g/dl, platelets 95 × 109 l–1, leukocytes 13.4 × 109 l–1, blast cells
30%. At presentation (day 12): platelets 87 × 109 l–1, leukocytes 19.1
× 109 l–1, blast cells 20% in PB, 30% in BM and immunophenotyping
showed weak expression of CD4 and CD45 and partly expression of
CD33, CD36, CD41 and CD61; CD13 was not expressed. Day 306 is
time of relapse.
lip. Details on blood counts and immunophenotyping of PB and bone
marrow (BM) at birth and day 12 are depicted in Fig. 1.
Conventional karyotyping (32 metaphases) and fluorescence in
situ hybridization (FISH) analysis using a chromosome 21-specific
probe LSI 21 (Abbott, Downers Grove, Illinois) (100 metaphases)
on phytohemagglutinin stimulated PB T-lymphocytes revealed nor-
mal female karyotype (46,XX) without (mosaic) trisomy 21; t(15;17),
t(8;21), inv(16), t(16;16), t(4;11), t(9;11), t(11;19), t(10;11) and young
age-related translocations t(8;16), t(7;12) and KMT2A-fusion tran-
scripts were absent. In addition, no GATA1, THPO, NPM1, FLT3-ITD,
C-KIT, CEPBA, WT1 or RAS gene mutations were identified. Spe-
cific acute megakaryoblastic leukemia (AMKL) related fusion genes
(i.e. NUP98/KDM5A, NUP98/NSD1, KAT6A/CREBBP, CBFA2T3/GLIS2,
RBM15/MKL1 and MNX/ETV6) were not found. GATA1 mutation
analysis (with detection limit of 5% in our hands) was negative.
The premature state of the child, the absence of clinical signs
and the absence of genetic/molecular aberrations associated with
AML/JMMLencouragedus to choose the carefulwatch-and-wait strat-
egy by consensus of the pediatric oncology team. The non-DS AMKL
clone resolved spontaneously and at the age of 4months, blood counts
had completely recovered and no clone could be identified by SNP
analysis anymore (Fig. 1). The cytogenic clone was no longer present
at days 83 and 132 (BM).
Based on the lack of recurrent aberrations by standard analy-
sis, an extended search for genomic alterations was performed using
CytoSNP-850K SNP array analysis (build Hg 19 BlueGnome R© , Illu-
mina Inc., San Diego, California) of PB (day 17/day 83) and BM (day
26/day 132). Copy number loss (CN-loss) of a 10.6 Mb region on
chromosome 5 (breakpoints, bands 5q31.1 and 5q31.3; minimally
deleted region 130,813,377-141,386,638(hg19), including the EGR1
gene) and CN-loss of a 17.0 Mb region on chromosome 8 (break-
points, bands 8q23.1 and 8q24.13; minimally deleted region 108,408,
409-125,438,835, including the EXT1 gene) were both identified in
approximately 30% of PB blasts (day 17) and 10% of BM blasts (day
26) (Fig. 2 and Supplementary Fig. S1). FISHanalysis using 5q31(EGR1)
and 8q24(EXT1) probes on metaphases (cultured PB, day 17) demon-
strated cryptic del(5)q anddel(8)q tobewithin the sameclone (datanot
shown). At days 83, 132 and 211, there was no longer evidence in this
patient for these deletions (PB and BM), demonstrating the somatic
natureof these subclonal, potential driversofmalignanthematopoiesis
and consistent with the transient nature of the AMKL.
At the age of 11 months, the patient developed AML M7 (47%
leukemic blasts, PB). Using chromosome banding, FISH and SNP anal-
yses (BM), the 8q24 clone was identified with a clonal evolution
(additional trisomy chromosome 6 and trisomy chromosome 19, 20%
mosaicism), as well as a second independent clone with copy-neutral
loss-of-heterozygosity (acquired uniparental disomy) of the long arm
of chromosome 5 (from band 5q11.2 to 5qter), with ∼25% mosaic
(Fig. 2c), but 5q31.1-5q31.3 negative. Currently, 4 months later, the
patient is in complete remission andMRD-negative after two cycles of
standard AML induction treatment.
3 DISCUSSION
The differential diagnosis of myeloid hyperproliferation in infants
includes JMML, AML (mainly FAB-M4, M5 and M7), TAM (DS) and
other types of TMD.6,35,36 The challenge in clinical practice is to sep-
arate transient from aggressive infant leukemia types that require
immediate intensive treatment. This discrimination can be hard in
patients who do not reveal typical genetic aberrations.
In our patient, amegakaryoblastic clone (AML-FAB-M7)was identi-
fied in the absence of a GATA1mutation and (mosaic) trisomy 21. The
possible option of transient leukemia (i.e. TMD) always needs to be
considered in such young children, especially inDS cases, inwhich case,
it is referred to as TAM.32 In non-DS TMD, only a few other recurrent
somatic or germline aberrations have been described. In patients with
non-M7-non-DS TMD, these include somatic t(8;16), trisomy 12 with
GATA1mutation, del(8)(q23.q24), del(5q) and del(13)(q13;q31), as well
as germline THPO mutations and del(13)(q12.11) aberrations. In our
patient, TMD-related aberrations and lack of clinical features allowed
to carefully watch-and-wait, but only after excluding typical somatic
translocations associated with aggressive AMLM7.7
Currently, a clinical guideline for suspected TMD cases including
genetic aberrations is being developed by the International Berlin-
Frankfurt-Müster-AML Study Group, based on a worldwide collection
of clinical and genetic data and reviewed literature (Supplementary
Table S1). We here show that, in addition to conventional genetic test-
ing such as karyotyping andmutational analyses, further genome-wide
analysis can aid in the confirmation of monoclonality in rare individual
non-DS TMD cases.
In our patient SNP array analysis at presentation revealed a somatic
cryptic deletion(5)(q31.1-q31.3), including theEGR1gene. It is conceiv-
able that the submicroscopic EGR1 gene size hampered the detection
of this aberration by conventional karyotyping. Future evaluations of
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F IGURE 2 SNP array profiles depicting the somatic 10.6Mb 5q31.1q31.3 deletions during time. A. PB at day 17 B. BM at day 26 C. PB at day 83
D. BM at day 132. PB, peripheral blood; BM, bone marrow; CN, copy number; BAF, bi-allele frequency. Somatic deletions are highlighted in pink,
subsequent alterations in BAF, indicative for the percentage of mosaicism, in purple, and regions with constitutional loss-of-heterozygosity (LOH)
>5Mb in yellow.
more infant AML cases are necessary to reveal the recurrence and
relevance of this gene for leukemogenesis in TMD.
The other identified aberration was del(8)(q23.2q24), which was
previously described once in TMD.8 This deletion harbors the EXT1
gene, which encodes a glycoprotein that enhances cellular growth,
adhesion, invasiveness and metastastic potential.9 EXT1 is considered
to be a tumor suppressor gene, and EXT1 downregulation by hyperme-
thylation of the EXT1 promotor has been shown to reduce heparan sul-
phate synthesis, thereby deregulating hematopoiesis.37 Interestingly,
one previous study in DS patients addressed the role of EXT1 hyper-
methylation in the progression of TMD to DS-AMKL.10 The fact that
clonal evolution (+6,+19) at time of AML recurrence in our patient at
the age of 11 months occurred in the clone harboring 8q(q23.2q24)
is suggestive of a leukemia-driving role of aforementioned genes at
that hotspot. This is underscored by the fact that the AML M7 pre-
sented transiently with one clone containing both the 5q- and 8q-,
whereas at reemergence the leukemiawas biclonal: one clonewith a de
novo acquired uniparental disomy 5q (25%mosaic) and one clone with
8q- (no 5q-,+19,+6 [20%mosaicism]).
Hence, we add combined 8(q23.2q24) and 5(q31.1q31.3) deletions
to the list of recurrent aberrations in which “’watch-and-wait” could
be considered in neonatal AMKL cases (Supplementary Table S1) with-
out trisomy 21 and mutated GATA1. It needs to be confirmed whether
such cases are at substantial risk to develop leukemia at a later stage
andwhat drives this clonal evolution. Therefore, ongoing international
collaboration remains important.
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